Brings Together Highly Accurate Short- and Long-Read Sequencing Technologies, Paving the Path to a More Perfect View of a Genome Pacific Biosciences’ Recent Advances with its Sequel SMRT ® Technology, Combined with Illumina’s Infrastructure, will Expand Biological Discovery and Clinical Insight

MENLO PARK, Calif. , Oct. 16, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its Third Quarter 2018 Financial Results on Thursday, November 1, 2018 , at 4:30pm Eastern Time .

Highlights include release of new chemistry and more than 25 presentations demonstrating utility of SMRT Sequencing for human genetics applications MENLO PARK, Calif. , Oct. 15, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leading provider of high-quality

Significant Enhancements to Sequel System Enable >99% Accuracy for Single-Molecule Reads up to 15 kb ; Throughput Increases by 2- to 4-Fold MENLO PARK, Calif. , Oct. 10, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leading provider of high-quality sequencing

Diploid Assembly of a Puerto Rican Female Adds a Rich Resource to Population-Specific Reference Genomes MENLO PARK, Calif. , Oct. 08, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and

High-quality reference genomes for thousands of plant, animal and microbial species to be created using SMRT Sequencing MENLO PARK, Calif., Sept. 13, 2018 (GLOBE NEWSWIRE) -- When creating a genomic ark of creatures great and small, scientists across the globe are turning to the comprehensive

MENLO PARK, Calif. , Sept. 12, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (the “Company”) today announced that it has priced its previously announced underwritten public offering of 14,117,647 shares of its common stock at a price to the public of $4.25 per

MENLO PARK, Calif. , Sept. 10, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.  Pacific Biosciences also intends to grant the underwriters a 30-day option

MENLO PARK, Calif. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its second quarter ended June 30, 2018 . Total revenue for the second quarter of 2018 was $21.6 million , compared to $20.1 million for the second

Industry Veteran Previous Served as EVP & Chief Commercial Officer of Illumina MENLO PARK, Calif. , July 31, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced